Almac adding 229 jobs in Irish CMO expansion

Almac is expanding its contract manufacturing presence in Ireland, spending about $21.5 million to bolster a production facility and add 229 jobs.

Over the next three years, Almac will scale up its drug development and manufacturing capacity in Craigavon, Ireland, riding high off strong sales for an undisclosed laxative drug it manufactures there.

Almac's other manufacturing plants are at full capacity, the company said, and soaring demand for the laxative has led the company to add high-volume bulk manufacturing technology to the facility, scheduled to come online in November. Separately, Almac is adding 13,400 square feet of formulation development and lab space to the Craigavon site, the company said.

"Centralising and expanding our production in Craigavon will mean more cost-effective manufacturing and optimal quality control and distribution," Almac President Graeme McBurney said in a statement. "... This latest addition makes Almac a much more attractive proposition to international clients who seek streamlined, one-stop drug development solutions."

Last year, Almac bolstered its API production at the same plant, adding two 1,000-liter reactors and a pressure-filter dryer, and, in February, the company notched FDA approval for a packaging operation in Audubon, PA, investing $10 million in the facility.

- read the announcement

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

The CRO will transfer most of its Pennsylvania-based biologics laboratory functions to a new, 73,000-square-foot site on Devon Park in Wayne.

Monoclonal antibodies developer Xencor extended a strategic alliance formed in 2016 with Selexis with four commercial license agreements.